13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001892770
Total reported value
$189.2M
$189.2M
85 檔
71.2%
As reported in its official Q2 2025 Form 13F filing, Knott David M Jr's tracked investment portfolio stood at $189.2M with 85 total positions.
During Q2 2025, Knott David M Jr's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including CLMT, APO, JAAA) accounted for 71.2% of total reported equity market value during Q2 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CLMT | Calumet Inc | Stock-Other | 23.39% | — | -0.67% | |
| 2 | APO | Apollo Global Management Inc | Stock-Financials | 14.47% | -0.85% | — | |
| 3 | JAAA | Janus Henderson Aaa Clo ETF | ETF-Other | 11.39% | -0.30% | -10.24% | |
| 4 | GOOG | Alphabet Inc-cl C | Stock-Comm Services | 9.02% | +1.46% | — | |
| 5 | JPM | Jpmorgan Chase & Co | Stock-Financials | 2.76% | -0.28% | — | |
| 6 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 2.36% | — | -37.50% | |
| 7 | XERS | Xeris Biopharma Holdings Inc | Stock-Other | 2.24% | +0.78% | -4.50% | |
| 8 | DCGO | Docgo Inc | Stock-Other | 2.19% | -0.27% | — | |
| 9 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 2.00% | +0.13% | +5.26% | |
| 10 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.74% | +1.93% | +14.04% | |
| 11 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 1.73% | -1.77% | EXIT | |
| 12 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 1.71% | — | — | |
| 13 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.57% | -0.32% | — | |
| 14 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.50% | -0.82% | +175.61% | |
| 15 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.35% | — | -27.69% | |
| 16 | ✓ | Inozyme Pharma Inc | Stock-Other | 1.21% | — | — | |
| 17 | ESGRP | Enstar Group Limited - Deposita | Stock-Other | 1.14% | — | — | |
| 18 | LENZ | Lenz Therapeutics Inc | Stock-Other | 1.09% | -0.18% | EXIT | |
| 19 | CSX | Csx CORP | Stock-Industrials | 1.04% | — | — | |
| 20 | AB | Alliancebernstein Holding LP | Stock-Other | 0.89% | -0.18% | — | |
| 21 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.86% | +0.26% | +8.33% | |
| 22 | PFE | Pfizer Inc | Stock-Healthcare | 0.82% | -0.13% | -70.72% | |
| 23 | ACLXGBX | Arcellx Inc | Stock-Other | 0.77% | -1.33% | EXIT | |
| 24 | ATRC | Atricure Inc | Stock-Other | 0.69% | -0.11% | +88.64% | |
| 25 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.67% | — | +85.00% | |
| 26 | ALKS | Alkermes plc | Stock-Healthcare | 0.64% | +0.84% | — | |
| 27 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.58% | -0.35% | +204.94% | |
| 28 | CLOZ | Eldridge Bbb-b Clo ETF | ETF-Other | 0.58% | -0.06% | — | |
| 29 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 0.57% | -0.43% | +42.11% | |
| 30 | RHP | Ryman Hospitality Properties | Stock-Real Estate | 0.54% | +0.03% | — | |
| 31 | LQDA | Liquidia CORP | Stock-Other | 0.51% | — | — | |
| 32 | JNJ | Johnson & Johnson | Stock-Healthcare | 0.48% | -0.06% | +650.76% | |
| 33 | MYGN | Myriad Genetics Inc | Stock-Other | 0.43% | — | +12.50% | |
| 34 | ABBV | Abbvie Inc | Stock-Healthcare | 0.42% | — | — | |
| 35 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.39% | -0.06% | EXIT | |
| 36 | CTVA | Corteva Inc | Stock-Materials | 0.37% | -0.01% | — | |
| 37 | MSFT | Microsoft CORP | Stock-Tech | 0.36% | -0.03% | — | |
| 38 | SLDB | Solid Biosciences Inc | Stock-Other | 0.36% | +0.10% | +23.06% | |
| 39 | KMB | Kimberly-clark CORP | Stock-Consumer Staples | 0.35% | — | — | |
| 40 | COLL | Collegium Pharmaceutical Inc | Stock-Other | 0.32% | — | -38.89% | |
| 41 | 6D8 | Dupont De Nemours Inc | Stock-Other | 0.29% | -0.10% | EXIT | |
| 42 | IBM | Intl Business Machines CORP | Stock-Tech | 0.29% | +0.01% | — | |
| 43 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.28% | — | — | |
| 44 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.28% | — | -35.71% | |
| 45 | MDLZ | Mondelez International, Inc. | Stock-Consumer Staples | 0.28% | — | — | |
| 46 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.27% | +0.23% | — | |
| 47 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.26% | +0.28% | +483.33% | |
| 48 | HELP | Cybin Inc | Stock-Other | 0.25% | +0.29% | — | |
| 49 | CNQ | Canadian Natural Resources | Stock-Energy | 0.24% | -0.14% | — | |
| 50 | AAPL | Apple Inc | Stock-Tech | 0.23% | — | — |
According to official SEC Form 13F filings, Knott David M Jr reported a total U.S. public equity portfolio value of $189.2M across 85 disclosed positions in Q2 2025.
During Q2 2025, Knott David M Jr's top holdings by market value included CLMT (23.4%)、APO (14.5%)、JAAA (11.4%). The largest single position, CLMT, represented 23.4% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q2 2025, Knott David M Jr made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.